Shanghai, China

Zhongren Ding

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Beijing Kbd Pharmaceuticals Co., Ltd.. Active years: 2016.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Zhongren Ding in Pharmaceutical Compounds

Introduction

Zhongren Ding is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address health issues related to platelet aggregation. His work is characterized by a focus on innovative solutions that can lead to effective treatments.

Latest Patents

Zhongren Ding holds a patent for "Ribofuranosyl purine compounds, methods for preparing the same and use thereof." This invention pertains to compounds that are useful in treating diseases associated with platelet aggregation. The patent outlines the process for preparing these compounds and their applications in pharmaceutical formulations aimed at improving patient outcomes.

Career Highlights

Zhongren Ding is associated with Beijing Kbd Pharmaceuticals Co., Ltd., where he applies his expertise in pharmaceutical research and development. His work has led to advancements in the creation of medicaments that can significantly impact the treatment of various medical conditions.

Collaborations

Throughout his career, Zhongren Ding has collaborated with esteemed colleagues such as Hongguang Du and Guocheng Liu. These partnerships have fostered a collaborative environment that enhances innovation and the development of new pharmaceutical solutions.

Conclusion

Zhongren Ding's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…